Search - tctmd.com

Displaying 341 - 360 of 420

Sort: Relevancy | Date

News Industry News

Abbott Announces Positive Results Of Its Naturally Dissolving Stent From Absorb Japan Study

September 01, 2015

Presentation ESC 2015

12 vs 48 months of dual antiplatelet therapy after drug-eluting stent placement: The OPTIDUAL Randomized Trial

Presenter: G?rard Helft

August 31, 2015

News Conference News ESC 2015

OPTIDUAL: No Clear Need to Lengthen DAPT to 4 Years After DES

Caitlin E. Cox

August 31, 2015

News Daily News

Subestudio BASKET-PROVE: Los SLF son Mejores que los SMD en Pacientes Ancianos con Arterias Grandes

Yael L. Maxwell

July 29, 2015

News Industry News

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

July 29, 2015

News Daily News

BASKET-PROVE 亚组研究：DES 对有大动脉的老年患者的治疗效果优于 BMS

Yael L. Maxwell

July 29, 2015

News Daily News

BASKET-PROVE Substudy: DES Better Than BMS in Elderly Patients With Large Arteries

Yael L. Maxwell

July 29, 2015

News Industry News

Eagle Pharmaceuticals’ RTU Bivalirudin NDA Accepted for Filing

July 23, 2015

News Industry News

Cardiome Submits Supplemental New Drug Submission (sNDS) For AGGRASTAT To Health Canada

July 22, 2015

News Industry News

Symic Biomedical Selects Vascular Clinical Candidate

July 20, 2015

News Industry News

Hospira Announces U.S. Launch of Generic Bivalirudin for Injection

July 16, 2015

News Industry News

The Medicines Company Authorizes Generic Launch of ANGIOMAX® (bivalirudin)

July 09, 2015

News Industry News

U.S. to vie with India for top bioabsorbable stent market after FDA approval

June 25, 2015

News Daily News

En Análisis ACCOAST Identifica los Factores asociados a Más Riesgos Hemorrágicos en el Manejo de Cuadros de SCASEST

Todd Neale

June 22, 2015

News Daily News

ACCOAST分析发现了NSTE-ACS患者更高出血风险的有关因素

Todd Neale

June 22, 2015

News Daily News

ACCOAST Analysis Identifies Factors Tied to Higher Bleeding Risks in NSTE-ACS

Todd Neale

June 22, 2015

News Industry News

Abbott Announces CE Mark for New Advancement of Absorb Stent System for People with Heart Disease

May 19, 2015

News Industry News

Antiplatelet Drug Ticagrelor More Effective Than Clopidogrel for Ad Hoc PCI Patients

May 07, 2015

Presentation

Antiplatelet Therapy Duration Following BMS or DES: The DAPT Randomized Clinical Trial

Presenter: D. J. Kereiakes

March 24, 2015

News Daily News

DAPT Substudy: No Apparent Benefit of Long-term DAPT in BMS Patients

Yael L. Maxwell

March 24, 2015

Advertisement

Abbott Announces Positive Results Of Its Naturally Dissolving Stent From Absorb Japan Study

12 vs 48 months of dual antiplatelet therapy after drug-eluting stent placement: The OPTIDUAL Randomized Trial

OPTIDUAL: No Clear Need to Lengthen DAPT to 4 Years After DES

Subestudio BASKET-PROVE: Los SLF son Mejores que los SMD en Pacientes Ancianos con Arterias Grandes

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

BASKET-PROVE 亚组研究：DES 对有大动脉的老年患者的治疗效果优于 BMS

BASKET-PROVE Substudy: DES Better Than BMS in Elderly Patients With Large Arteries

Eagle Pharmaceuticals’ RTU Bivalirudin NDA Accepted for Filing

Cardiome Submits Supplemental New Drug Submission (sNDS) For AGGRASTAT To Health Canada

Symic Biomedical Selects Vascular Clinical Candidate

Hospira Announces U.S. Launch of Generic Bivalirudin for Injection

The Medicines Company Authorizes Generic Launch of ANGIOMAX® (bivalirudin)

U.S. to vie with India for top bioabsorbable stent market after FDA approval

En Análisis ACCOAST Identifica los Factores asociados a Más Riesgos Hemorrágicos en el Manejo de Cuadros de SCASEST

ACCOAST分析发现了NSTE-ACS患者更高出血风险的有关因素

ACCOAST Analysis Identifies Factors Tied to Higher Bleeding Risks in NSTE-ACS

Abbott Announces CE Mark for New Advancement of Absorb Stent System for People with Heart Disease

Antiplatelet Drug Ticagrelor More Effective Than Clopidogrel for Ad Hoc PCI Patients

Antiplatelet Therapy Duration Following BMS or DES: The DAPT Randomized Clinical Trial

DAPT Substudy: No Apparent Benefit of Long-term DAPT in BMS Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content